Patents Examined by Shirley V. Gembeh
-
Patent number: 11992556Abstract: This invention relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children. The aerosol composition comprises ciclesonide, ethanol and either 1, 1, 1, 2-tetrafluoroethane, or 1, 1, 1, 2, 3, 3, 3-heptafluoropropane.Type: GrantFiled: May 13, 2021Date of Patent: May 28, 2024Assignee: Covis Pharma GmbHInventors: Helgert Müller, Renate Engelstätter, Ulrich Bildmann, Andrea Bauer, Paul McGlynn
-
Patent number: 11992501Abstract: Pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. The pharmaceutical compositions contain nonabsorbable compositions and may be used, for example, to treat diseases or other metabolic conditions in which removal of protons, the conjugate base of a strong acid and/or a strong acid from the gastrointestinal tract would provide physiological benefits such as normalizing serum bicarbonate concentrations and the blood pH in an animal, including a human.Type: GrantFiled: September 24, 2021Date of Patent: May 28, 2024Assignee: Renosis, Inc.Inventors: Gerrit Klaerner, Eric F. Connor, Randi K. Gbur, Matthew J. Kade, Paul H. Kierstead, Jerry M. Buysse, Michael J. Cope, Kalpesh N. Biyani, Son H. Nguyen, Scott M. Tabakman
-
Patent number: 11992577Abstract: The present disclosure provides medical products including an adhesive containing a carboxyalkyl cellulose and sorbitol. Such medical products can find use as a bolster material for use in conjunction with a surgical fastening device such as a stapler. Such adhesives may include advantageous properties such as the ability to retain tack while stored under a peelable cover. Related methods of manufacture and use are also described.Type: GrantFiled: July 27, 2021Date of Patent: May 28, 2024Assignee: Cook Biotech IncorporatedInventors: Loran Solorio, Steven Cohen, Benjamin Patrick Kline
-
Patent number: 11992480Abstract: A method for altering the PK profile of a pharmaceutical formulation containing a PDE-4 inhibitor, such as roflumilast, to reduce the spike in Cmax. The spike in Cmax is reduced by topically administering the PDE-4 inhibitor in combination with one or more phosphate ester surfactants. Reducing the spike in Cmax will reduce gastrointestinal side effects and result in better patient compliance.Type: GrantFiled: May 21, 2021Date of Patent: May 28, 2024Assignee: ARCUTIS BIOTHERAPEUTICS, INC.Inventors: David W. Osborne, Howard Welgus
-
Patent number: 11985999Abstract: A method of improving flavor of a combination of a composition for increasing circulating ketone levels is disclosed. A composition containing (D)-?-hydroxybutyric acid (D-BHB), (D)-?-hydroxyvaleric acid (D-BHV), and (D)-1,3 butanediol (D-1,3BD) is disclosed. Exemplary compositions may be incorporated into food, supplement, and beverage products.Type: GrantFiled: October 11, 2021Date of Patent: May 21, 2024Assignee: VITANAV, INC.Inventors: Devon Price, Peter Bayne
-
Patent number: 11986446Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.Type: GrantFiled: December 27, 2021Date of Patent: May 21, 2024Assignee: Jazz Pharmaceuticals Ireland LimitedInventor: Mark Eller
-
Patent number: 11986003Abstract: A synthetic nutritional composition comprising a phospholipid and/or a metabolic precursor and/or metabolite thereof for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential, and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.Type: GrantFiled: February 23, 2022Date of Patent: May 21, 2024Assignee: Societe des Produits Nestle S.A.Inventors: Nora Schneider, Jonas Hauser, Sean Deoni, Tamas Bartfai, Jonathan O'Regan
-
Patent number: 11987404Abstract: The present invention regards a method for filling containers with a single-dose composition comprising or, alternatively, consisting of mannitol in powder form. Such process comprises the following steps: a) breaking up a coherent mass of powder mannitol, so as to obtain a broken-up mass from said coherent mass; c) filling a plurality of containers with the broken-up mass of step a), wherein a bulk density of the coherent mass is smaller than a bulk density of the broken-up mass.Type: GrantFiled: February 26, 2020Date of Patent: May 21, 2024Assignee: NTC S.R.L.Inventors: Luciano Marcelloni, Federico Bertocchi
-
Patent number: 11980691Abstract: Enteric softgel capsules comprise a fill material and an enteric shell composition, characterized in that the enteric nature of the capsules may be achieved without an enteric coating or added conventional enteric polymers.Type: GrantFiled: March 15, 2019Date of Patent: May 14, 2024Assignee: R.P. Scherer Technologies, LLCInventors: Toshikazu Okayama, Miyako Takahashi, Takuma Fujii
-
Patent number: 11980596Abstract: The present invention provides devices and methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.Type: GrantFiled: December 15, 2020Date of Patent: May 14, 2024Assignee: Janssen Pharmaceutica NVInventors: Jingli Wang, Michael Cannamela, Hong Yan, Rochelle Kleinberg
-
Patent number: 11976300Abstract: Disclosed is the use of a water-soluble realgar solid dispersion in the preparation of an erythroid differentiation inducer for bone marrow hematopoietic stem cells and/or bone marrow hematopoietic progenitor cells. The water-soluble realgar solid dispersion is prepared from raw materials comprising 1 part by weight of realgar, 1-20 parts by weight of a polymer, and 0-5 parts by weight of a surfactant. The water-soluble realgar solid dispersion can induce bone marrow hematopoietic stem and/or progenitor cells to be differentiated into red blood cells, promote the accumulation of red blood cells in bone marrow cells, effectively alleviate the decrease in the number of red blood cells caused by the suppression of the erythroid differentiation of bone marrow hematopoietic stem and/or progenitor cells, improve anemia caused by hematopoietic failure, and protect bone marrow cells from the killing effect.Type: GrantFiled: April 11, 2019Date of Patent: May 7, 2024Assignee: INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Haiyan Xu, Jian Liu, Tao Wang, Bing Han, Jie Meng, Tao Wen
-
Patent number: 11975092Abstract: The instant disclosure relates to hair treatment compositions that include a unique combination of components that function to impart desirable cosmetic properties to the hair. The hair treatment compositions typically include: at least 0.5 wt. % of at least one non-polymeric mono, di, or tricarboxylic acid, and/or a salt thereof; one or more amines selected from the group consisting of diamines, polyamines, alkylamines, alkanolamines, and a mixture thereof; one or more fructan polysaccharides; one or more prosolvents; and water.Type: GrantFiled: August 16, 2021Date of Patent: May 7, 2024Assignee: L'OREALInventors: Barbara Mitchell, Anand Ramchandra Mahadeshwar, Jacob Gordon
-
Patent number: 11969442Abstract: Covid-19 binding aerosols are provided. The Covid-19 binding aerosols include Fe3O4 microparticles, at least one organoselenium compound, at least one essential oil, and incense. The Covid-19 binding aerosols may be formulated for use in any product that is capable of emitting aerosols, including but not limited to as air fresheners, as incense, or the like. The Fe3O4 microparticles may have an average size of 5,000 nm-10,000 nm (between 5-10 ?m). The Covid-19 binding aerosols are formulated as aerosol compositions having an average size of greater than 60 ?m-100 ?m to ensure effective binding to virions.Type: GrantFiled: July 7, 2023Date of Patent: April 30, 2024Assignee: KING FAISAL UNIVERSITYInventors: Hany Mohamed Abd El-Lateef Ahmed, Saadeldin Elsayed Ibrahim Shabaan, Jihad Wadai Saleh Alessa
-
Patent number: 11969001Abstract: The invention relates to a process for producing food ingredients from Stevia rebaudiana plant and their use in food products, beverages and other consumables. Obtained compositions are useful as flavors, sweeteners, antioxidants, and other functional ingredients.Type: GrantFiled: August 27, 2020Date of Patent: April 30, 2024Assignee: PURECIRCLE USA INC.Inventors: Avetik Markosyan, Yeen Yee Wong, Pei Chen Koh
-
Patent number: 11965178Abstract: In some embodiments provided herein is a method of preparing cargo-loaded platelets, comprising: treating platelets with a cargo and with a loading buffer comprising a salt, a base, a loading agent, and optionally ethanol, to form the cargo-loaded platelets.Type: GrantFiled: November 27, 2019Date of Patent: April 23, 2024Assignee: Cellphire, Inc.Inventors: Keith Andrew Moskowitz, Rafael Jorda, Ying Yi Zheng, Daniel Allen Sheik
-
Patent number: 11964033Abstract: A method of providing a treatment for cleaning and removing oils from hair includes providing a cosmetic that includes a blend of a powder phase including at least two absorbents selected from the group of mica, silica, starch, talc, kaolin and zeolite, and at least one emollient with a solvent phase. The blended powder and solvent phases are formed into a dry shampoo product adapted for manual application to the hair. A porous mold may be used to provide the cosmetic. Techniques may be applied to other forms of cosmetic compositions.Type: GrantFiled: October 19, 2021Date of Patent: April 23, 2024Assignee: Mana Products, Inc.Inventors: George Lambridis, Julio Pina
-
Patent number: 11958871Abstract: The present invention relates to novel compounds which are particularly useful as inhibitors of bacterial glutaminyl cyclases (bacQC); pharmaceutical compositions comprising such compounds; compounds and/or pharmaceutical compositions for use in methods for treatment, in particular for use in the treatment of periodontitis and related conditions; as well as to crystals comprising bacterial glutaminyl cyclases, methods for identifying candidate compounds which may associate with the binding pocket of a bacQC and/or are bacQC inhibitors.Type: GrantFiled: February 22, 2019Date of Patent: April 16, 2024Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.Inventors: Christian Jäger, Linda Liebe, Daniel Ramsbeck, Miriam Linnert, Stefanie Geissler, Anke Piechotta, Diane Meitzner, Holger Cynis, Mirko Buchholz
-
Patent number: 11951110Abstract: Described are methods of preparing reduced 3,7-diamino-10H-phenothiazine (DAPTZ) compounds of formula: wherein: R1 and R9 are independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: —H; C1-4alkyl; C2-4alkenyl; and halogenated C1-4alkyl; each of HX1 and HX2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These methods are particularly useful for producing stable reduced forms, and with high purity. The stability and purity are especially relevant for pharmaceutical compositions for the treatment of disease. The compounds are useful for treatment of e.g. tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs.Type: GrantFiled: February 2, 2022Date of Patent: April 9, 2024Assignee: WisTa Laboratories Ltd.Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley, John Mervyn David Storey, Colin Marshall, James Peter Sinclair, Thomas Craven Baddeley
-
Patent number: 11950611Abstract: The invention relates to a process for producing highly soluble compositions containing purified steviol glycosides from Stevia rebaudiana Bertoni plant extract, more particularly Rebaudioside D. Obtained highly soluble compositions are useful as non-caloric sweeteners or in combination with sugar or high intensity sweeteners in edible and chewable compositions such as beverages, confectionaries, bakery products, chewing gums and the like.Type: GrantFiled: February 24, 2022Date of Patent: April 9, 2024Assignee: PURECIRCLE SDN BHDInventors: Avetik Markosyan, Siddhartha Purkayastha
-
Patent number: 11951227Abstract: Coated and expanded, nanofiber structures are provided and methods of use thereof.Type: GrantFiled: April 4, 2022Date of Patent: April 9, 2024Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Jingwei Xie, Shixuan Chen, Mark Carlson